Pennsylvania
Cancer biologic therapy trials in Pennsylvania
97 cancer biologic therapy studies are recruiting participants at sites in 68 cities across Pennsylvania as of November 18, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Browse Pennsylvania by city
Cities with the most studies recruiting right now.
Philadelphia
60 studies recruiting.
Pittsburgh
48 studies recruiting.
Every Pennsylvania city with a recruiting study
By research area: Lung Cancer (34), Lymphoma (31), Breast Cancer (15), Melanoma (11), Prostate Cancer (4), Pancreatic Cancer (2).
Philadelphia (60), Pittsburgh (48), Allentown (17), Danville (15), Hershey (13), York (13), Bethlehem (12), Monroeville (12), Erie (11), Wilkes-Barre (11), Chambersburg (10), Ephrata (10), Greensburg (10), Lebanon (10), Dickson City (9), Gettysburg (9), Lewisburg (9), Mechanicsburg (9), Harrisburg (8), Hazleton (8), Wynnewood (8), Bryn Mawr (7), East Stroudsburg (7), Media (7), Paoli (7), Sayre (7), Scranton (7), West Reading (7), Willow Grove (7), Indiana (6), Washington (6), Beaver (5), Cranberry Township (5), Hanover (5), Johnstown (5), Lancaster (5), N. Huntingdon (5), Natrona Heights (5), Seneca (5), West Mifflin (5), Williamsport (5), Butler (4), Farrell (4), McKeesport (4), Moon Township (4), New Castle (4), Uniontown (4), Altoona (3), Carlisle (3), Chadds Ford (3), Jefferson Hills (3), Meadville (3), Mount Pleasant (3), Phoenixville (3), Wexford (3), Meadowbrook (2), Pottsville (2), Reading (2), Bala-Cynwyd (1), East Norriton (1), Easton (1), Fountain Hill (1), Horsham (1), North Huntingdon (1), Pottstown (1), Quakertown (1), Sellersville (1), Stroudsburg (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Breast cancer: recently updated in Pennsylvania
Basic details from each study's public record (the 12 most recently updated of 97). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Pittsburgh
- Registry record
- NCT03606967 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Allentown · Altoona · Bethlehem · and 14 more U.S. locations
- Registry record
- NCT05564377 · updated
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Philadelphia · York
- Registry record
- NCT06393374 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Pennsylvania on ClinicalTrials.gov.
Lung cancer: recently updated in Pennsylvania
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Allentown · Bethlehem · Bryn Mawr · and 13 more U.S. locations
- Registry record
- NCT06498635 · updated
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Recruiting in
- Philadelphia · Pittsburgh
- Registry record
- NCT06767514 · updated
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Bethlehem · Philadelphia
- Registry record
- NCT06422143 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Bethlehem
- Registry record
- NCT06623422 · updated
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Pittsburgh
- Registry record
- NCT06287775 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Pennsylvania on ClinicalTrials.gov.
Prostate cancer: recently updated in Pennsylvania
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Allentown · Bethlehem · East Stroudsburg · and 6 more U.S. locations
- Registry record
- NCT03866382 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Pennsylvania on ClinicalTrials.gov.
Lymphoma: recently updated in Pennsylvania
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Allentown · Danville · Hershey · and 2 more U.S. locations
- Registry record
- NCT06317662 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Philadelphia
- Registry record
- NCT06337318 · updated
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Recruiting in
- Philadelphia
- Registry record
- NCT07478848 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Pennsylvania on ClinicalTrials.gov.
Ask about studies in Pennsylvania
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections